Group 1 - The company plans to globally offer 37.91 million shares, with 3.79 million shares available in Hong Kong and 34.12 million shares for international sale [1] - The subscription period is set from December 2 to December 5, with a maximum offer price of HKD 26.38 per share, and an entry fee of approximately HKD 2,664.60 for 100 shares [1] - The total expected fundraising amount is HKD 1 billion, with a net amount of HKD 922 million, which will be used for R&D and commercialization of core products, enhancing production capacity, and general corporate purposes [1] Group 2 - The company is a clinical-stage biotechnology firm focused on developing and providing recombinant biopharmaceuticals in China, targeting complex diseases with limited treatment options [2] - The projected net profits for the fiscal years 2023, 2024, and the first half of 2025 are estimated at -160 million, -364 million, and -183 million respectively [2] - The company is expected to be listed on the main board by December 10, 2025, with joint sponsors including CITIC Securities (Hong Kong) and Haitong International Capital [1]
宝济药业-B(02659.HK)拟全球发售3791.17万股 12月2日起招股
Zheng Quan Shi Bao Wang·2025-12-02 01:47